Paul Tudor Jones’s Inovio Pharmaceuticals INO Stock Holding History

Paul Tudor Jones’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$330K	Buy	+300,000	New	+$356K	﹤0.01%	3064

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Paul Tudor Jones's INO Position: Q1 2024 in Review

Paul Tudor Jones sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 11,235 shares — an estimated $68.8K sold.

Paul Tudor Jones first reported a position in INO in Q1 2014 and held it in 19 quarters. The position peaked at $1.96M in Q3 2021. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

Paul Tudor Jones reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Paul Tudor Jones sold 11,235 Inovio Pharmaceuticals shares in Q1 2024, an estimated $68.8K.
Paul Tudor Jones first reported a position in Inovio Pharmaceuticals in Q1 2014 and held it in 19 quarters.
Paul Tudor Jones's Inovio Pharmaceuticals position peaked at $1.96M in Q3 2021.
89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Tudor Investment Corp's 13F filing for Q1 2024, filed 15 May 2024.